AlaskaDenise
In Memoriam
I earlier posted something about this concept in the "other mammals" thread.
http://www.earthtimes.org/articles/show/news_press_release,6490.shtml
<TABLE cellSpacing=0 cellPadding=1 width="99%" align=center border=0><TBODY><TR><TD bgColor=#f7f7f7>[FONT=Verdana, Arial, Helvetica, sans-serif]MediVas, LLC Announces Positive Preclinical Ferret Data Against H5N1 [/FONT]</TD></TR><TR><TD bgColor=#fbfbfb><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD width="83%">[FONT=Verdana, Arial, Helvetica, sans-serif]Posted on : Wed, 18 Oct 2006 15:56:00 GMT | Author : MediVas, LLC
News Category : PressRelease [/FONT][FONT=Verdana, Arial, Helvetica, sans-serif][/FONT]</TD><TD vAlign=bottom width="17%">[FONT=Verdana, Arial, Helvetica, sans-serif]
[/FONT]</TD></TR></TBODY></TABLE></TD></TR><TR><TD>[FONT=Verdana, Arial, Helvetica, sans-serif]
[/FONT]<TABLE cellSpacing=2 cellPadding=0 width="100%" border=0><TBODY><TR vAlign=top><TD>SAN DIEGO, Oct. 18 -- MediVas, LLC, today announced promising data from a preclinical H5N1 vaccine study in ferrets performed at Battelle Memorial Institute's Medical Research and Evaluation Facility in Columbus, Ohio. For this study, MediVas utilized its novel, synthetic subunit vaccine, which provides an alternative to traditional egg-based vaccines. The vaccine used the company's patented biodegradable polymer technology in a particle form with purified recombinant hemagglutinin (HA) and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. This technology allows MediVas to produce a vaccine against any mutated influenza virus in as a short as five weeks.
Commenting on the results, Kenneth W. Carpenter, MediVas' President and CEO said, "These outstanding results represent a significant achievement in the development of our next-generation pandemic flu vaccine. These data validate our novel technology and, in particular, our lead intranasal formulation, which showed a 100% survival rate, presents a meaningful advance in vaccine technology. With the high antibody response and exceptional survival results achieved across all formulations in this study, coupled with our ability for low cost manufacture, storage and transport of our subunit vaccines, MediVas is poised to deliver a breakthrough in the fight against avian and seasonal flu."
</TD></TR></TBODY></TABLE>
</TD></TR></TBODY></TABLE>
http://www.earthtimes.org/articles/show/news_press_release,6490.shtml
<TABLE cellSpacing=0 cellPadding=1 width="99%" align=center border=0><TBODY><TR><TD bgColor=#f7f7f7>[FONT=Verdana, Arial, Helvetica, sans-serif]MediVas, LLC Announces Positive Preclinical Ferret Data Against H5N1 [/FONT]</TD></TR><TR><TD bgColor=#fbfbfb><TABLE cellSpacing=0 cellPadding=0 width="100%" border=0><TBODY><TR><TD width="83%">[FONT=Verdana, Arial, Helvetica, sans-serif]Posted on : Wed, 18 Oct 2006 15:56:00 GMT | Author : MediVas, LLC
News Category : PressRelease [/FONT][FONT=Verdana, Arial, Helvetica, sans-serif][/FONT]</TD><TD vAlign=bottom width="17%">[FONT=Verdana, Arial, Helvetica, sans-serif]
[/FONT]</TD></TR></TBODY></TABLE></TD></TR><TR><TD>[FONT=Verdana, Arial, Helvetica, sans-serif][/FONT]<TABLE cellSpacing=2 cellPadding=0 width="100%" border=0><TBODY><TR vAlign=top><TD>SAN DIEGO, Oct. 18 -- MediVas, LLC, today announced promising data from a preclinical H5N1 vaccine study in ferrets performed at Battelle Memorial Institute's Medical Research and Evaluation Facility in Columbus, Ohio. For this study, MediVas utilized its novel, synthetic subunit vaccine, which provides an alternative to traditional egg-based vaccines. The vaccine used the company's patented biodegradable polymer technology in a particle form with purified recombinant hemagglutinin (HA) and nucleoprotein (NP) from the A/Vietnam/1203/2004 virus. This technology allows MediVas to produce a vaccine against any mutated influenza virus in as a short as five weeks.
Commenting on the results, Kenneth W. Carpenter, MediVas' President and CEO said, "These outstanding results represent a significant achievement in the development of our next-generation pandemic flu vaccine. These data validate our novel technology and, in particular, our lead intranasal formulation, which showed a 100% survival rate, presents a meaningful advance in vaccine technology. With the high antibody response and exceptional survival results achieved across all formulations in this study, coupled with our ability for low cost manufacture, storage and transport of our subunit vaccines, MediVas is poised to deliver a breakthrough in the fight against avian and seasonal flu."
</TD></TR></TBODY></TABLE>
</TD></TR></TBODY></TABLE>